{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.5","value":"833.2"},{"groupId":"OG001","spread":"26.4","value":"1078.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Alisertib 25 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days (D) followed by a 7-day recovery period in 28-day cycles until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG000","title":"Alisertib 25mg PIC QD 21D"},{"description":"Alisertib 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG001","title":"Alisertib 35 mg PIC QD 21D"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) evaluable population included all participants for whom there were sufficient dosing and alisertib concentration time data to permit non-compartmental PK analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 predose and at multiple timepoints (up to 24 hours) postdose","title":"Cmax: Maximum Observed Concentration for Alisertib as Pill in Capsule (PIC) With Once Daily for 21 Days (QD21D) Dosing at Day 1","type":"PRIMARY","unitOfMeasure":"nM"}